Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 4,153 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,153 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $35.30, for a total transaction of $146,600.90. Following the completion of the transaction, the insider now directly owns 161,497 shares of the company’s stock, valued at approximately $5,700,844.10. The trade was a 2.51 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total value of $1,619,174.70.
• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total value of $70,055.70.

Hims & Hers Health Stock Up 7.7 %

Shares of HIMS stock traded up $3.01 during mid-day trading on Tuesday, hitting $41.94. 16,419,084 shares of the company’s stock were exchanged, compared to its average volume of 11,104,599. The stock has a 50-day simple moving average of $29.35 and a two-hundred day simple moving average of $22.70. Hims & Hers Health, Inc. has a fifty-two week low of $8.51 and a fifty-two week high of $41.98. The stock has a market cap of $9.16 billion, a price-to-earnings ratio of 95.32 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s quarterly revenue was up 77.1% on a year-over-year basis. During the same period last year, the company earned ($0.04) earnings per share. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Main Management ETF Advisors LLC acquired a new position in shares of Hims & Hers Health in the 3rd quarter valued at about $672,000. Robeco Institutional Asset Management B.V. purchased a new stake in Hims & Hers Health during the third quarter worth approximately $604,000. Carnegie Investment Counsel acquired a new stake in shares of Hims & Hers Health in the third quarter worth $5,531,000. Royce & Associates LP raised its stake in shares of Hims & Hers Health by 17.0% in the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after acquiring an additional 49,500 shares during the period. Finally, Versor Investments LP acquired a new position in shares of Hims & Hers Health during the 3rd quarter valued at $634,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HIMS has been the topic of a number of analyst reports. Canaccord Genuity Group raised their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. TD Cowen reaffirmed a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price target for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Finally, BTIG Research started coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.